Uzbek scientists’ drug included in the protocol for treatment of coronavirus

The Ministry of Health approved the use of the drug on recommendation of a doctor in treating coronavirus patients, as well as at the first signs of weakness associated with an acute respiratory infection. It is derived from the Rhus coriaria plant and has been shown in clinical trials to be effective against various strains of the influenza virus and SARS-Cov-2.

Clinical trials have shown that the drug can be used from the age of seven, and taking pills 2 times a day helps prevent the reproduction of the virus, further colds and inflammations, acute and atypical pneumonia. 

It is also able to stop the two main conservative enzymes involved in the formation of all functional and structural proteins of the virus that have a pathological effect – 3CL protease and RNA-dependent RNA polymerase. Structural and functional proteins do not appear in the body and immature viruses are formed that do not have the ability to infect. 

The drug has expressed antihypoxic, membrane-stabilizing, anti-radical, antioxidant properties. The level of toxicity is very low, there are practically no side effects.